Analysis of CTC numbers at the different time points showed that the one measurement that was statistically significantly associated with progression - free survival was a change in the number of CTCs with
ALK copy number gain over time.
All patients had both CTCs with ALK rearrangements and CTCs with
ALK copy number gain before treatment and at two months.
Median progression - free survival for the 13 patients who had a decrease in the number of CTCs with
ALK copy number gain was 14.0 months, while the median progression - free survival for the 16 patients who had stable or increased numbers of CTCs with
ALK copy number gain was 6.1 months.
Not exact matches
After enriching for CTCs, the researchers analyzed the samples for
ALK rearrangements and for an increase in the number of
copies of the
ALK gene.
Among patients with non-small cell lung cancer (NSCLC) fueled by
ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased
copies of the
ALK gene over the first two months of treatment was associated with increased progression - free survival.